SLN · XBRL financial data

Silence Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (SLN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	—	—	21,655	31,643	43,258	559
Cost of goods and services sold	—	—	13,463	12,867	11,810	215
Gross profit	—	—	8,192	18,776	31,448	344
Research and development	—	—	43,550	56,937	67,883	67,753
General and administrative	—	—	25,682	26,222	26,884	22,344
Operating income (loss)	—	—	(61,040)	(64,383)	(63,319)	(91,077)
Income tax expense (benefit)	—	—	688	956	845	11
Net income (loss)	—	—	(50,334)	(54,228)	(45,309)	(88,612)
Earnings per share, basic USD per share	—	—	(0.52)	(0.49)	(0.33)	(0.63)
Earnings per share, diluted USD per share	—	—	(0.52)	(0.49)	(0.33)	(0.63)
Weighted average shares, basic thousands of shares	—	—	96,585	111,277	138,752	141,695
Weighted average shares, diluted thousands of shares	—	—	96,585	111,277	138,752	141,695
Revenue thousands of GBP	5,300	—	—	—	—	—
Cost of sales thousands of GBP	3,762	7,456	10,880	10,318	—	—
Gross profit thousands of GBP	1,717	4,959	6,621	15,057	—	—
Research and development thousands of GBP	20,209	30,765	35,605	44,025	—	—
Operating profit (loss) thousands of GBP	(35,847)	(45,814)	(48,593)	(49,604)	—	—
Profit (loss) thousands of GBP	(32,547)	(39,410)	(40,489)	(43,267)	—	—

Fiscal years (SLN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	—	—	—	68,789	121,330	11,277
Short-term investments	—	—	—	—	26,004	73,837
Accounts receivable	—	—	—	290	972	0
Total current assets	—	—	—	103,151	187,366	118,658
Property and equipment, net	—	—	—	1,938	1,818	1,581
Right-of-use asset	—	—	—	370	157	167
Goodwill	—	—	9,683	9,981	9,392	10,621
Total assets	—	—	—	119,448	202,635	131,442
Total current liabilities	—	—	—	22,336	16,822	13,613
Lease liability, non-current	—	—	—	118	0	71
Total liabilities	—	—	—	97,455	68,612	69,138
Accumulated deficit	—	—	—	(431,894)	(474,044)	(562,572)
Total stockholders' equity	—	12,374	27,221	21,993	134,023	62,304
Total liabilities and equity	—	—	—	119,448	202,635	131,442
Common shares outstanding (cover page) thousands of shares	83,306	89,785	107,808	118,847	141,674	141,702
Cash and cash equivalents thousands of GBP	27,449	73,537	54,816	54,031	—	—
Total current assets thousands of GBP	76,399	86,333	96,686	81,021	—	—
Total current liabilities thousands of GBP	25,575	15,167	21,943	17,769	—	—
Total equity thousands of GBP	9,059	8,526	22,072	17,050	—	—

Fiscal years (SLN's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	—	—	(50,334)	(54,228)	(45,309)	(88,612)
Stock-based compensation	—	—	12,686	16,274	16,307	8,074
Net cash from operating activities	—	—	(57,044)	(49,462)	(67,640)	(62,271)
Purchases of property and equipment	—	—	173	56	211	55
Net cash from investing activities	—	—	(20,498)	19,294	(21,966)	(47,992)
Proceeds from issuing common stock	—	—	52,581	31,937	142,087	15
Net cash from financing activities	—	—	52,581	31,937	142,087	15
Net cash from operating activities thousands of GBP	(10,776)	6,806	(45,456)	(39,350)	—	—
Net cash from investing activities thousands of GBP	9,618	8,676	(16,542)	16,430	—	—
Net cash from financing activities thousands of GBP	15,428	30,711	43,049	25,155	—	—

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Silence Therapeutics	72,054	0	1,518*	141.7M	—	Q2 FY26 10-QJun 30, 2026
Cardiff Oncology	9,197	104	(11,765)*	77.8M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Tvardi Therapeutics	15,765	not reported	(9,228)*	13.3M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Rezolute	10,615	not reported	(13,146)*	96.7M	8.2 quarters	Q4 FY26 10-KJun 30, 2026
Natures Sunshine Products	82,503	116,985	835*	17.6M	—	Q2 FY26 10-QJun 30, 2026
Rocket Pharmaceuticals	224,507	0	(39,613)*	109.8M	7.2 quarters	Q2 FY26 10-QJun 30, 2026
Perspective Therapeutics	48,488	not reported	(20,650)*	114.2M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Esperion Therapeutics	156,158	80,104	(27,722)	257.4M	5.6 quarters	Q1 FY26 10-QMar 31, 2026
Palvella Therapeutics	187,803	not reported	(12,845)*	14.4M	19.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.